SCHEMBL7786267

SCHEMBL7786267

COc1ccc2c(c1)-c1cccc(OC)c1C2=O

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 6/20 0.56
ALDH1A1 P00352 5/20 0.56
MEN1 O00255 5/20 0.56
KMT2A Q03164 5/20 0.56
TDP1 Q9NUW8 2/20 0.56
KDM4E B2RXH2 1/20 0.56
USP2 O75604 1/20 0.56
DUSP3 P51452 1/20 0.56
EGFR P00533 1/20 0.54
PIM1 P11309 1/20 0.54
RAB9A P51151 4/20 0.54
SMN1; SMN2 Q16637 3/20 0.54
BACE1 P56817 1/20 0.50
ELANE P08246 1/20 0.49
CYP1A2 P05177 2/20 0.49
CYP3A4 P08684 2/20 0.49
GAPDH P04406 1/20 0.48
MAPK1 P28482 2/20 0.48
L3MBTL1 Q9Y468 1/20 0.48
NPC1 O15118 2/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11266728 0.92 EGFR (0.56) MAPTALDH1A1MEN1KMT2ATDP1
SCHEMBL11271335 0.92 EGFR (0.56) MAPTALDH1A1MEN1KMT2ATDP1
SCHEMBL27740829 0.88 CYP1A2 (0.55) MAPTALDH1A1MEN1KMT2ARAB9A
SCHEMBL7792661 0.87 MEN1 (0.55) MAPTALDH1A1MEN1KMT2ATDP1
SCHEMBL7792409 0.85 MEN1 (0.57) MAPTALDH1A1MEN1KMT2ATDP1
SCHEMBL28191369 0.83 CYP1A2 (0.53) MAPTALDH1A1MEN1KMT2ARAB9A
SCHEMBL9264626 0.83 MAPT (0.74) MAPTALDH1A1MEN1KMT2ATDP1
SCHEMBL29002782 0.83 MAPT (0.54) MAPTALDH1A1MEN1KMT2ATDP1
SCHEMBL3417492 0.80 EGFR (0.76) MAPTALDH1A1MEN1KMT2ATDP1
SCHEMBL612831 0.79 MAPT (0.74) MAPTALDH1A1MEN1KMT2ATDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-109700791-A Hongmaoxinjian is preparing the application in anti-benign prostatic hyperplasis drug 西安交通大学 2019-05-03 CN disclosed
US-20010037037-A1 Oximesulfonic acid esters and the use thereof as latent sulfonic acids CIBA SPEICIALTY CHEMICALS CORP. 2001-11-01 US disclosed
US-6017675-A POLYMERIZATION CATALYST CIBA SPECIALTY CHEMIALS CORPORATION (US) 2000-01-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20010037037-A1 Oximesulfonic acid esters and the use thereof as latent sulfonic acids QSOX1, HAO2, PAH MAPT 4475/4885ALDH1A1 160/4885MEN1 4038/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.